Table 1. Clinicopathologic characteristics according to plasma PSMA-positive EV concentration.
| Variables | Overall | Plasma PSMA-positive EV concentration | ||
|---|---|---|---|---|
| Low | High | p-value | ||
| Diagnosis (%) | <0.001 | |||
| BPH | 28 (25.5) | 28 (38.4) | 0 (0) | |
| PCa | 82 (74.5) | 45 (61.6) | 37 (100) | |
| Age (years)* | 68.8 (±7.2) | 69.7 (±7.2) | 68.3 (±6.6) | 0.406 |
| BMI (kg/m2)* | 23.3 (±2.6) | 23.3 (±2.8) | 23.3 (±2.7) | 0.942 |
| Preoperative PSA (ng/mL)* | 11.0 (±16.7) | 10.4 (±23.5) | 13.2 (±13.9) | 0.095 |
| Prostate volume (mL)*,† | 43.7 (±24.1) | 50.2 (±23.1) | 33.4 (±12.4) | <0.001 |
| Pathologic T stage (%) | 0.625 | |||
| 2 | 59 (71.7) | 23 (76.7) | 36 (69.2) | |
| 3 | 22 (26.7) | 7 (23.3) | 15 (28.8) | |
| 4 | 1 (1.7) | 0 (0) | 1 (1.9) | |
| Pathologic Gleason score (%) | 0.025 | |||
| ≤6 | 19 (23.2) | 12 (40.0) | 7 (13.5) | |
| 7 (3 + 4) | 25 (30.5) | 6 (20.0) | 19 (36.5) | |
| 7 (4 + 3) | 23 (28.0) | 9 (30.0) | 14 (26.9) | |
| ≥8 | 15 (18.3) | 3 (10.0) | 12 (23.1) | |
| PSMA-positive areas (%) | 14.7 (±9.4) | 8.1 (±8.7) | 22.3 (±10.7) | <0.001 |
*Values are expressed as mean (±SD).
†Prostate volume was measured by transrectal ultrasonography.
BPH, benign prostatic hyperplasia; PCa, prostate cancer; BMI, body mass index; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen.